Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 7
Submit an article Journal homepage
794
Views
5
CrossRef citations to date
0
Altmetric
Original Article: Research

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

Gregory F. GuzauskasDepartment of Pharmacy, University of Washington, Seattle, WA, USA; ORCID Iconhttp://orcid.org/0000-0002-9095-1672View further author information
ORCID Icon,
Anthony MasaquelGenentech, Inc., South San Francisco, CA, USA; View further author information
,
Per-Olof ThuressonF. Hoffmann-La Roche Ltd., Basel, SwitzerlandView further author information
,
Keith DawsonGenentech, Inc., South San Francisco, CA, USA; View further author information
&
David L. VeenstraDepartment of Pharmacy, University of Washington, Seattle, WA, USA; Correspondence[email protected]
View further author information
Pages 1668-1676 | Received 06 Apr 2018, Accepted 14 Nov 2018, Published online: 11 Jan 2019

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Shinya Ohno, Ayako Shoji, Kiyohiko Hatake, Naoko Oya & Ataru Igarashi. (2020) Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients. Journal of Medical Economics 23:10, pages 1130-1141.
Read now

Articles from other publishers (4)

Scott J SpencerGregory F GuzauskasFederico FeLizziAino LaunonenKeith DawsonDavid L VeenstraAnthony Masaquel. (2021) Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. Journal of Managed Care & Specialty Pharmacy 27:5, pages 615-624.
Crossref
Sarah Hofmann, Sebastian Himmler, Dennis Ostwald, Ulrich Dünzinger, Aino Launonen & Per-Olof Thuresson. (2020) The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany. Journal of Comparative Effectiveness Research 9:14, pages 1017-1026.
Crossref
Shigeo Fuji. (2020) Answer to Simulation Analysis of Cost-Effectiveness in 2012 Has Finally Come in 2019. Journal of Clinical Oncology 38:5, pages 522-522.
Crossref
Juliet Bell. (2015) Perspectives on the Treatment of Mantle Cell Lymphoma and Follicular Lymphoma in 2015 and Beyond. EMJ Hematology, pages 54-64.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.